Awardee OrganizationSTATE UNIVERSITY OF NEW YORK AT BUFFALO
Description
Abstract Text
Murine natural resistance to hemopoietic allografts, including F1 hybrid
resistance to parental grafts, is a manifestation of natural killer (NK)
cell's alloreactivity. The genetic basis of natural resistance has long
been a puzzle, because the resistance is specific and is controlled by
genes linked to the H-2, the mouse major histocompatibility complex (MHC).
Recent studies by us and others suggest that H-2 class I molecules are the
major determinants that control the specificity of this resistance. In
fact, our study suggests that the prototypical hybrid resistance of
B6D2F1(H-2b/d) mice to parental B6 (H-2b) graft is mostly, although not
completely, mediated by NK cells expressing Ly-49A, a receptor that
receives an inhibitory signal from Dd and Dk. Thus, the absence of
particular class I molecules appears to define the specificity of this
resistance, rather than positive recognition of putative target
determinants controlled by the Hh-1 locus. This view is also supported by
another study of ours in which Dd-loss variant clones of cell lines
derived from parental DBA/2 (H-2d) and syngeneic B6D2F1 mice were found to
express a phenotype indistinguishable from that of parental B6. The
results indicate that susceptibility to killing by B6D2F1 NK cells does
not require genes specific for H-2b. This favors the concept that lack of
Dd expression is the necessary and sufficient condition for the
susceptible phenotype hitherto known as Hh-1b. The nature of the
receptors expressed by Ly-49A subset of B6-specific B6D2F1 effectors and
the structural requirements of the Dd molecule that prevents the
recognition by Ly-49A+ and Ly-49A- subsets of these effectors, will be
examined as one of the objectives of the proposed studies. Our preliminary
results also suggest that similar resistance of B6 mice against BALB/c (H-
2d) cells may be controlled by a different mechanism, possibly involving
an H-2-independent determinant and a determinant which is positively
contributed by the Dd molecule. Analysis of this resistance is therefore
the second main objective of the proposed studies. Finally, we propose to
analyze murine NK cell alloreactivity and its relationship to the spectrum
of Ly-49 family members expressed at the level of single clones. This is
based on our preliminary results, in which multiple Ly-49 transcripts were
detected by RT-PCR in single clones. These studies, therefore, are
designed to elucidate the molecular basis of the specific murine natural
resistance against hemopoietic stem cells and neoplasm, and will hopefully
suggest a means of reducing bone marrow allograft failure in man.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
DUNS Number
038633251
UEI
LMCJKRFW5R81
Project Start Date
01-May-1977
Project End Date
31-March-2000
Budget Start Date
01-April-1998
Budget End Date
31-March-1999
Project Funding Information for 1998
Total Funding
$209,112
Direct Costs
$137,574
Indirect Costs
$71,538
Year
Funding IC
FY Total Cost by IC
1998
National Institute of Diabetes and Digestive and Kidney Diseases
$209,112
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01DK013969-28
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01DK013969-28
Patents
No Patents information available for 5R01DK013969-28
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01DK013969-28
Clinical Studies
No Clinical Studies information available for 5R01DK013969-28
News and More
Related News Releases
No news release information available for 5R01DK013969-28
History
No Historical information available for 5R01DK013969-28
Similar Projects
No Similar Projects information available for 5R01DK013969-28